(NasdaqGM:HROW), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Harrow and certain of its officers and/or directors have engaged […]

(NASDAQ:ABL), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Abacus and certain of its officers and/or directors

(NASDAQ:SLP), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or the “Company”) (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Simulations Plus and certain of its officers and/or

(NASDAQ:JSPR), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Jasper and certain of its officers and/or directors have

(NASDAQ:MREO), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or directors

(NYSE:GSK), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors have engaged

(NASDAQ:RARE), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have

(NYSE:ZK), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of ZEEKR Intelligent Technology Holding Limited (“Zeekr” or the “Company”) (NYSE: ZK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zeekr and certain of its officers and/or

(Other OTC:GELYY),(Other OTC:GELYF), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Geely Automobile Holdings Limited (“Geely” or the “Company”) (OTCMKTS: GELYF; GELYY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Geely and certain of its

(NYSE:WPP), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of WPP plc (“WPP” or the “Company”) (NYSE: WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether WPP and certain of its officers and/or directors have engaged